U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...

I was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was – did the company have any designs on entering the viral vector-based gene therapy ...

Barrett only joined Novartis in January from Pfizer but said that she is unwilling to relocate to Basel where Novartis’ oncology headquarters is based, and has instead accepted a leadership role ...

Roche headquarters in Basel, Switzerland ... trigger for change was an unexpected approach from rival Swiss drugmaker Novartis in the early 2000s. The family’s first reaction was: “We ...

San Francisco, California, and its parent, Basel-based Roche ... was fully developed in-house at the Boston headquarters of the Novartis Institutes of Biomedical Research (NIBR).

Swiss pharmaceutical firm Novartis said on Tuesday that it has agreed to buy privately held, clinical-stage US biotech Anthos ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

According to iSpot.TV’s analysis of January TV drug ad spending data, Novartis’ prostate cancer drug Pluvicto swooped in to take the No. 1 spot on the list, with more than $47 million spent ...

BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company said it ...

Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late ...

with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillationAcquisition adds a late-stage asset and is aligned with Novartis strategic focus ...